Source: Virtual Congress 2021 – COVID - 19 treatments



Rating:

Share or cite this content

Citations should be made in the following way:
S. Lukyanov (Chita (Zabaykalsky Krai), Russian Federation), K. Shapovalov (Chita (Zabaykalsky Krai), Russian Federation), P. Tereshkov (Chita (Zabaykalsky Krai), Russian Federation), Y. Smolyakov (Chita (Zabaykalsky Krai), Russian Federation), A. Vanchikova (Chita (Zabaykalsky Krai), Russian Federation), B. Kuznik (Chita (Zabaykalsky Krai), Russian Federation). Thymalin as an immunomodulation option in severe COVID-19. 3667

Member's Comments

No comment yet.

Related content which might interest you: The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Immunomodulating therapy and the risk of severe pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 353s Year: 2002 Immunosuppressive therapy after human lung transplantation Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=105 Year: 2003 Immunosuppressive therapy after human lung transplantation Source: Eur Respir J 2004; 23: 159-171 Year: 2004 Ciclosporin as a steroid sparing agent in children with difficult to treat asthma Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Etiology and etiotropic therapy of angiogenic sepsis Source: Eur Respir J 2003; 22: Suppl. 45, 452s Year: 2003 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006 Fenspiride as complementary anti-inflammatory agent in therapy of patients with chronic obstructive pulmonary disease Source: Annual Congress 2011 - COPD management Year: 2011 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017 Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004